VPPIPP and IPPVPP: Two Hexapeptides Innovated to Exert Antihypertensive Activity

Fengyun Ding1,2,*, Bingjun Qian1,3,*, Xin Zhao1, Shanqi Shen1, Yun Deng1,3, Danfeng Wang1, Feng Zhang1, Zhongquan Su1,3, Pu Jing1,3*

1 Department of Food Science and Engineering, School of Agriculture and Biology, Shanghai Jiao Tong University, Shanghai, China, 2 Yancheng Institute of Health Sciences, Jiangsu, China, 3 Bor Luh Food Safety Center, Shanghai Jiao Tong University, Shanghai, China

Abstract

In this study, two hexapeptides of IPPVPP and VPPIPP were innovated by using two commercial antihypertensive peptides IPP and VPP as two domains cis-linked and trans-linked, respectively. The IPPVPP and VPPIPP were chemically synthesized and evaluated for the antihypertensive activity in vitro/vivo. The in vitro ACE-inhibitory study showed that VPPIPP (34.71±4.38%) has a significantly stronger activity than that of IPPVPP (13.17±0.25%) at a treatment concentration of 10 μmol/L, but it was weaker than the commercial IPP (56.97±2.40%) (P<0.05). However, VPPIPP, IPPVPP, and IPP lowered the systolic blood pressure by 21±0.9%, 17.4±1.3% and 17.5±0.9%, respectively, in rats at 1.5 mg/kg body weight dosage. The result was consistent with the mRNA level of sarcoplasmic reticulum Ca2+-ATPase Gene (SERCA 2a) in rat hearts. Additionally, IPPVPP and VPPIPP showed no negative impact on blood glycometabolism. The results suggested that the two hexapeptides could be potent bioactive peptides in functional foods for people with high blood pressure.

Citation: Ding F, Qian B, Zhao X, Shen S, Deng Y, et al. (2013) VPPIPP and IPPVPP: Two Hexapeptides Innovated to Exert Antihypertensive Activity. PLoS ONE 8(4): e62384. doi:10.1371/journal.pone.0062384

Editor: Luis Eduardo M. Quintas, Universidade Federal do Rio de Janeiro, Brazil

Received September 7, 2012; Accepted March 21, 2013; Published April 30, 2013

Copyright: © 2013 Ding et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was jointly supported by the Shanghai Municipal Natural Science Foundation (grant no. 11ZR1416200), the National Natural Science Foundation of China (grant no. 31071530), and the Youth Foundation of the School of Agriculture and Biology of Shanghai Jiao Tong University (NQN201001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: bjqianfd@sjtu.edu.cn (BQ); pjcolumbus@gmail.com (PJ)

† These authors contributed equally to this work.

Introduction

Hypertension is a world-wide health issue encountered by different ages of people and becomes one of the most important preventable causes of premature morbidity and mortality. According to the World Health Organization’s 2012 World Health Statistics, the population with hypertension has drastically increased from 600 million in 1980 to nearly 1 billion in 2008 in both developed and developing countries. One in three adults worldwide and half of adults in some Africa countries have high blood pressure, and it is estimated to cause 7.5 million deaths, about 12.8% of all annual deaths worldwide [1]. Not surprisingly, it has gained top public and scientific concern due to its prevalence and risk of cardiovascular disease and death.

Studies on the mechanism of the hypertension occurrence revealed that the angiotensin converting enzyme (ACE), a component of the renin-angiotensin system (RAS), catalyzes the formation of the strong vasoconstrictor angiotensin II (Ang II) from angiotensin I (Ang I), contributing to the maintenance of normal blood pressure [2]. Therefore, ACE has become the major target of medicine in the clinical treatment of hypertension, and some ACE-inhibitors were developed, such as captopril, enalapril, lisinopril, tenormin, and temocapril. However, with the prolonged usage, they might produce side-effects to some patients, causing dry-cough, headache, dizziness, itching and rash [3].

In the past decades, researchers have focused on the natural nutraceutical resources and investigated the potential antihypertensive activity in vitro by ACE-inhibitory activity [4,5]. Some natural phytochemicals from plants, including rutin, quercetin glycoside, epicatechin-tetramer and cyanidin-3-O-sambubioside have been extensively studied as a substitute for chemo-pharmaceuticals [6–8]. Also, some antihypertensive peptides have been identified from hydrolyzed or fermented milk and other dietary sources [9]. Among them, the Isoleucine-Proline-Proline (IPP) and Valine-Proline-Proline (VPP) with IC50 of 5μmol/L and 9μmol/L were the typical ones. They are generally recognized as safe (GRAS) by the U.S. Food and Drug Administration (FDA) and have been approved for use in foods to help reduce blood vessel constriction [10].

Most ACE-inhibitory peptides contain 3 to 9 amino acid residues, whereas the good antihypertensive peptides from milk have 6 to 10 residues. It is shown that the peptide structure properties including C-terminal amino acid sequence have critical impact on the ACE-inhibitory activity in previous research. The C-terminal of the most natural ACE-inhibitory peptides is Ala-Pro or Pro-Pro residues [11–19], and the high ACE-inhibitory activity peptides derived from tuna myoprotein [11], cheese protein [15], and wheat protein [19] all have the Pro residue C-terminal, indicating that the ACE-inhibitory peptides with Pro in the C-terminal position appeared with a great activity. Additionally, the ACE-inhibitory peptides from casein always have hydrophobic amino acid residues at each of the three C-terminal positions, suggesting that the hydrophobicity is another factor important for the ACE-inhibitory peptide activity. Besides, peptides with...
Materials and Methods

Materials and chemicals

The tripeptides (IPP and VPP) and hexapeptides (IPPVPP and VPPIPP) used in this study were chemically synthesized by GL Biochem (Shanghai) Ltd (Shanghai, China) and their purity was more than 95%. The spontaneously hypertensive, strain SHR/Slac male rats aged 20 weeks were purchased from Shanghai Slac Laboratory Animal Co. Ltd. (Shanghai, China). Chemical reagents were from Sigma Chemical Co. (Louis, USA) and Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Hippuryl-l-histidyl-l-leucine (HHL) and Hippuric acid (HA) were obtained from Sigma Chemical Co. (Louis, USA).

Preparation of ACE from rabbit lungs and determination of enzyme activity

ACE extracts were prepared and its activity was determined according to the method of Nakamura et al. [22] and Wu & Ding [23] with some modifications. Briefly, the fresh rabbit lung without connective tissues was cut into pieces and washed with precooled NaCl (0.7%) to get rid of blood. The tissue pieces were homogenized in precooled 5-fold the volume of fresh rabbit lung weight (v/w, mL/g) of 100 mM sodium borate buffer (pH 8.3). The mixtures were then filtrated with 3-ply gauze followed by ultracentrifuged for 40 min (40,000 g, at 4°C). The supernatant as crude ACE extracts was retained and stored at 5°C [24].

The ACE activity was assayed using the method described by Wu & Ding [23]. It was based on the hydrolysis of hippuryl-L-histidyl-leucine (HHL) by ACE to hippuric acid (HA) and histidyl-leucine (HL) as products. The HA release from HHL was directly related to the ACE activity. One unit (U) of ACE was defined as the amount of enzyme catalyzing the release of 1 μmol/L HA from the substrate HHL per minute at 37°C. Briefly, 30 μL of ACE crude extracts were mixed with 100 μL of BBS (pH 8.3). The mixture was incubated at 37°C for 10 min. Then, 200 μL of 5 mM HCl/LL HHL solution substrate were added and the reaction mixture was incubated at 37°C for 20 min. The reaction was stopped by the addition of 250 μL of 1 mol/L HCl. 10 μL of solution were analyzed by reversed-phase HPLC and detected at the wavelength of λ = 228 nm. The mixture was incubated at 37°C for 10 min, after which 200 μL of 5 mM HHL solution substrate were added and the reaction mixture was incubated at 37°C for 20 min. Finally, 230 μL of 1 mol/L HCl were added to stop the reaction and 10 μL of solution were used to analyze HA release from HHL by reversed-phase HPLC with the same condition described above and detected at the wavelength of λ = 228 nm. Controls with equal volume of BBS as sample substitute were included for each measurement, and the blank experiment was executed with premixing 250 μL of 1 mol/L HCl and 2 μL of ACE crude extracts to inhibit the activity of ACE, firstly.

The evaluation of ACE inhibition was based on the measurement of the HA peak areas, and the degree of ACE inhibition (%) was calculated according to Eq.1:

\[
\text{ACE inhibition rate (\%)} = \left(\frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}} - A_{\text{blank}}}\right) \times 100
\]

Where \(A_{\text{control}}\) was the HA peak area of the buffer instead of tested samples, \(A_{\text{blank}}\) was the HA peak area of the reaction blank when HCl was added before HHL, and \(A_{\text{sample}}\) was the HA peak area of tested samples.

Ethics statement

All animal studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Shanghai Jiao Tong University School of Pharmacy. The protocol was approved by Shanghai Municipal Science and Technology Commission, the Shanghai Municipal Laboratory Animal Management Office (Permit Number: 11ZR1416200), and the Committee on the Ethics of Animal Experiments of the Shanghai Jiao Tong University School of Agriculture and Biology (Permit Number: NQN2010001).

Assay of blood pressure of SHR in vivo

The spontaneously hypertensive, strain SHR/Slac male rats (Production Permit Number: SCXXK (Shanghai) 2007-0005; Body weight, average ~400 g; Age, 20 weeks old) were purchased from Shanghai SLAC Laboratory Animal Co. Ltd. (Shanghai, China). The SHR were housed in cages and maintained under specific pathogen-free conditions on a cycle of 12 h of light and 12 h of darkness at Center of Experimental Animal, School of Pharmacy, Shanghai Jiao Tong University (Use Permit Number: SYXK (Shanghai) 2007-0025). The temperature and humidity in the cages were controlled at 24 ± 1°C and 60 ± 5%, respectively. SHRs were acclimatized for 7 days prior to experimentation. The rats were fed a standard laboratory diet (SLACOM; Shanghai, China), and tap water was freely available. After the hexapeptide water-solution (dose, 1.5 mg/kg body weight) injection with intragastric administration in six SHR, the systolic blood pressure (SBP) of each rat was measured by the tail-cuff method with a programmable electrophysgmomanometer (model SoftronBP-98A; Softron Beijing Incorporated, Beijing, China) at 1 h interval. A heater lamp was on the tail to improve signal quality. To obtain an accurate SBP reading, rats were first habituated to the SBP measurement device. Definitive measurements began when rats
remained unperturbed into the chamber throughout the inflation-deflation cycles. The SBP in each SHR with administration of distilled water (2 mL) was used as the control value. The data are expressed as means and standard errors (n = 6).

To evaluate whether the lowering SBP effect was the dose-dependence relative to the test peptides, the SHR were also treated with 0.75 mg/kg BW peptides water-solution as above program. And the relative lowering SBP effect was calculated as the following equation (Eq.2):

\[
\text{Relative lowering SBP rate} \% = \left( \frac{\text{SBP}_{\text{initial}} - \text{SBP}_{\text{lowest}}}{\text{SBP}_{\text{initial}}} \right) \times 100
\]

where SBP_{initial} is the initial SBP values of SHR right before the peptide administration, SBP_{lowest} is the lowest SBP value obtained within 5 h after the administration with the tested peptides.

Quantitative real-time-PCR analysis of \textit{SERCA 2a} gene

Total RNA was isolated from heart peeled from the SHR 3 h after fed with the tripeptide IPP, hexapeptides IPPVPP, or VPPPP using Trizol reagent (Generay) as instructed by the supplier. After treatment with DNase (Promega), 0.3 mg RNA was employed to synthesize the oligo (dT) primed first-strand cDNA using the ReverTra Ace-a-First Strand cDNA synthesis kit (TOYOBO). Quantitative real-time-PCR (qRT-PCR) analysis was performed using SYBR Premix EX Taq (TaKaRa) on a Rotor-Gene RG3000A detection system (Corbett Research) as described by Zhang et al. (2010) with the exception of the annealing temperature at 58 °C when using the primers SERCAF (5'-TCTGACTTTGTTGCGTG-3') and SERCAR (5'-GCCCTTGTATCCCCAGTGA-3') [25,26]. Gene GAPDH was used as reference gene with primer GAPDHF (5'-CCATGGAGAAGGCTGGG-3') and GAPDHR (5'-CAAAATTTGTGATGATGACC-3') [26]. Three biological replicates were used, and each with three technical repeats.

Effect of tripeptides on blood glucose level \textit{in vivo}

To evaluate the effect of the selected tripeptides on glycometabolism after administration \textit{in vivo}, the SHRs were tail bled 3.5 h after administration with the selected tripeptides at a dose of 1.5 mg/kg BW, and blood glucose level was determined by One Touch Ultra test strips using the One Touch Ultra blood Glucose monitoring system (LifeScan, Inc. Milpitas, USA).

---

**Table 1. ACE Inhibitory Activity of the Screened Peptides \textit{in vitro}.**

| Peptides | ACE inhibition rate (%) |
|----------|-------------------------|
| IPP      | 56.97 ± 2.40\(^a\)     |
| VPP      | 37.62 ± 6.68\(^a\)     |
| IPPVPP   | 13.17 ± 0.25\(^a\)     |
| VPPPP    | 34.71 ± 4.38\(^a\)     |

ACE inhibition rate (%) was expressed as mean ± SD. Values with the same letters are not significantly different (P<0.05) using LSD.

doi:10.1371/journal.pone.0062384.t001

---

**Figure 1. Lowering SBP effect of single oral administration of IPPVPP and VPPPP on SHR spontaneously hypertensive rats.** IPPVPP, VPPPP, and IPP (the positive control) were fed to the three groups of SHR with at a dose of 1.5 mg/kg BW, respectively; the distilled water as the control was fed to a SHR group at the same dosage. The SBP was expressed as mean ± SD. Points with the same letters mean no significant difference (P<0.05).

doi:10.1371/journal.pone.0062384.g001
Statistical analysis

Three replicate trials for each experiment were performed. Analysis of variance was performed and means separated using software SPSS version 14.0. Significant difference (P<0.05) between means were identified using least significant difference (LSD) procedures.

Results and Discussion

ACE-inhibitory activity assay of selected hexapeptides in vitro

To evaluate the antihypertensive activity of the innovated hexapeptides, the two hexapeptides (IPPVPP and VPPIPP) and the commercialized tripeptides (IPP and VPP as positive controls) were chemically synthesized to test its ACE inhibitory activity in vitro. The VPPIPP and IPPVPP showed different ACE inhibitory activity comparing to the commercial IPP and VPP at the treatment concentration of 10 μmol/L (Table 1), following an order: IPP (56.97%)>VPP (37.62%)=VPPIPP (34.71%)>IPPVPP (13.17%) at the 0.05 level by least significant difference test (Tukey HSD). In our test system, the ACE inhibitory activity of IPP and VPP at 10 μmol/L, used as positive controls, was a little weaker than that reported by Nakamura et al. [22]. The ACE-inhibitory activity of IPP (56.97%) was significantly stronger than that of VPP (37.62%) as two positive controls (P<0.05), indicating that the test system worked well. However, the values of IPP and VPP were slightly weaker than those reported by Nakamura et al. [22], which might attribute to the differences in detection assays, substrates, test conditions, or/and ACE origins [27].

Previous studies described that hydrophobic amino acids at each of the three C-terminal positions of antihypertensive peptide candidates were favorable, largely because Pro at the ultimate C-terminal position could gave them resistance to digestion in gastrointestinal tract and also improve exceptionally the affinity to ACE [28,29]. Therefore, the antihypertensive activity of the two hexapeptides was further analyzed in vivo using SHR rats.

Effect of IPPVPP and VPPIPP on blood pressure in SHR

To investigate the blood pressure lowering effect of the hexapeptides (IPPVPP and VPPIPP), male SHRs were administrated intragastrically with the hexapeptide water-solutions. The SBP of SHRs had been all decreased significantly within 2–3 hrs after administration (P<0.05) [Figure 1]. The SBP recovered to the initial state 5 h after administration. It showed that the antihypertensive effect of these products was transient. The lowest SBP values were obtained at the time of 2, 2, 3, and 3 h for the control, VPPIPP, IPPVPP, and IPP, respectively. The result showed that VPPIPP decreased the SBP from 193±3.7 mmHg as low as to 152±3.1 mmHg, exhibiting the strongest antihypertensive activity (P<0.05). IPPVPP (SBP_{lowest}=164±4.4 mmHg) showed no significant difference from the IPP (SBP_{lowest}=161±3.1 mmHg). The IPP reduced SBP from 195±6.2 mmHg to 161±3.1 mmHg (1.5 mg/kg BW dosage), although less effective than results reported by Nakamura et al. (1995) that IPP decreased the SBP of SHR by 21.7±4.1 mmHg (0.3 mg/kg BW dosage) in SHR [30]. In the present study, VPPIPP that decreased SBP by 41 mmHg (dose: 1.5 mg/kg BW) in SHR, was comparable or even better than antihypertensive peptides reported in previous studies [31–33]. Maeno et al. (1996) reported that administration of 2 mg/kg BW of heptapeptide KVLPVPQ (β-casein 169–175aa) resulted in a maximal decrease in SBP by 31.5±5.6 mmHg in SHR [31]. Abukabar et al. (1998) demonstrated that proteinase K hydrolysate of whey had the ability to reduce SBP by 55±2.6 mmHg, following an administration of 8 mg/kg BW in SHR [32]. Nurminen et al. (2000) showed that the whey protein derived tetrapeptide YGLF could reduce SBP by 23±4 mmHg.
following subcutaneous administration of 0.1 mg/kg BW in SHR [33]. The decrease in the SBP observed for captopril (antihypertensive positive control, 50 mg/kg) was about 53±4 mmHg in male SHR 4-6 h after administration [34]. Those suggest that VPPIPP was potent to be commercialized as antihypertensive peptide in future.

Apparently the VPPIPP even showed a significantly greater effect on the lowering SBP than the commercialized IPP in vivo (P<0.05), and it was not consistent to the result of ACE-inhibitory activity in vitro, which might attribute to the hydrolysis of VPPIPP by peptidase in intestinal tract or its instability in the blood or other mechanisms [27]. We also proposed that the VPPIPP hydrolysate might contain the active fragment such as IPP, which was already proved to be one of the strongest antihypertensive potential peptide [10]. Secondly, the C-domain catalytic sites of the somatic form of ACE are the susceptible bonds around Pro, Phe and His of Ang I (DRVYIHPFHL) [27], whereas VPPIPP has a good chance to generate the hydrolysate with a Pro at the fourth position started from the carboxyl terminal end, structurally similar to Ang I. That might be a competitive factor additionally contributing to the lowering SBP effect of VPPIPP. Those inferences need to be confirmed in future study. Additionally, it was noticed that the lowest SBP in our study was reached 1 h earlier than that the report by Nakamura et al., possibly due to the different forms of fed samples. In the study we applied a water solution, whereas Nakamura et al. used a viscous aqueous sodium caseinate solution that might result in a delayed absorption [30].

To better differentiate the lowering SBP effect of tested peptides and understand the dose-effect relationship, the relative lowering SBP rate (% equation described in the section of materials and methods) was generated to illustrate the effect of tested samples on the lowering SBP. A higher value of relative lowering SBP indicates a greater activity. Figure 2 showed that VPPIPP still had a significantly greater effect than others did at 1.5 mg/kg BW dosage (P<0.05). However, VPPIPP did not show significantly different from IPPVPP and IPP at 0.75 mg/kg BW dosage. Additionally, both VPPIPP and IPP showed a dose-dependent effect on lowering rat SBP (P<0.05) whereas IPPVPP did not. However, additional work needs to be done on a lower effective dosage(<0.75 mg/kg BW) of the tested hexapeptides in future.

Transcriptional regulation on SERCA 2a gene of hexapeptides

To further evaluate the antihypertensive function of the tested peptides, mRNA level of SERCA 2a gene in SHRs heart tissue was analyzed by Real-time PCR. In Figure 3, the transcriptional levels

![Figure 3. Quantitative PCR analysis of mRNA level of SERCA 2a gene.](https://doi.org/10.1371/journal.pone.0062384.g003)

**Table 2.** Analysis of Effect on Blood Glucose Level of SHR Fed with IPPVPP and VPPIPP.

| SHR groups | Blood Glucose Concentration (mmol/L) |
|------------|---------------------------------------|
| IPP        | 3.55±0.45*                            |
| IPPVPP     | 4.20±0.60*                            |
| VPPIPP     | 4.30±0.15*                            |
| Control    | 4.00±0.30*                            |

IPP, IPPVPP and VPPIPP represented the SHR groups fed with peptides of IPP, IPPVPP and VPPIPP, respectively, at dose of 1.5 mg/kg BW; control group was fed with distilled water. Blood glucose level was expressed as mean ± SD. Values with the same letters are not significantly different (P<0.05) using LSD. doi:10.1371/journal.pone.0062384.t002
of SERCA 2a gene for VPPIPP and IPPVPP groups were 3.98 and 2.70 times of the control, respectively (P<0.05). The VPPIPP groups showed no difference from IPP group (3.98 times of the control) in the transcriptional level of SERCA 2a gene, but significantly greater than IPPVPP (P<0.05). In the myocardial tissue, Ang II receptor (AT1) is the key element for the cardiocytes to detect angiotensin from Ang II and to induce signal transduction which could regulate some corresponding gene expression level [35]. Cui et al. [26] reported that Ang II infused could down-regulate transcriptional level of SERCA 2a gene in rat models of cardiac hypertrophy, which was mediated by AT1. In the renin-angiotensin system, ACE can convert Ang I to the potent vasoconstrictor, Ang II, to increase blood pressure [2]. Based on those previous reports and our results, we proposed that VPPIPP, IPPVPP and IPP might competitively inhibit ACE from catalyzing the conversion of Ang I into Ang II in vivo. Consequently, the reduction of Ang II could down-regulate transcriptional level of the gene for VPPIPP and IPPVPP groups were 3.98 and 3.5 h after administration (P<0.05), suggesting that the designed peptides had no negative effect on glycometabolism, just as same as captopril that has been proved by McGrowder et al. [39] to have no significant effect on postprandial blood glucose levels in the normoglycemic and normotensive animal model. The VPPIPP and IPPVPP are potent antihypertensive nutriceuticals.

Acknowledgments

We thank Prof. Dabing Zhang's help and his laboratory for quantitative real-time PCR technique support.

Author Contributions

Conceived and designed the experiments: BQ. Performed the experiments: ED XZ. SS FZ. Analyzed the data: BQ PJ. Contributed reagents/materials/analysis tools: YD ZS DW.

References

1. World Health Organization: World Health Statistics (2012) WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland.
2. Skeggs LT, Kahn JE, Shumway NP (1956) The preparation and function of the angiotensin-converting enzyme. J Exp Med 103: 295–299.
3. Peralta MS, Peralta AS, Flores EV, De La Higuera G, Trujillo P, et al. (2010) Inhibition of angiotensin I-converting enzyme inhibitory activities of enzymatic hydrolysates from wheat gliadin hydrolysate. Nahrung 54: 371–375.
4. Fujita H, Yokoyama T, Yoshikawa M (2000) Antioxidative activities and antiinflammatory activities of angiotensin I-converting enzyme inhibitory peptides derived from porcine skeletal muscle hydrolysates. J Nutri Food 4: 51–61.
5. Nagai T, Suzuki N, Nagashima T (2006) Antioxidative activities and angiotensin I-converting enzyme inhibitory activities of enzymatic hydrolysates from commercially available Kamaboko species. Food Sci Technol 42: 183–186.
6. Fujita H, Yokoyama T, Yoshikawa M (2000) Antioxidative activities and antiinflammatory activities of angiotensin I-converting enzyme inhibitory peptides derived from food proteins. J Food Sci Technol 12: 356–369.
7. Nakashima Y, Arihara K, Sasaki A, Mio H, Ishikawa S, et al. (2002) Antihypertensive activities of peptides derived from porcine skeletal muscle myosin in spontaneously hypertensive rats. J Food Sci 67: 434–437.
8. Muray RA, Fitzgerald RJ (2000) Angiotensin converting enzyme inhibitory peptides derived from food proteins: bioactivity bioactivity and production. Curr Pharm Des 6: 773–791.
9. Abubakar A, Saito T, Kitazawa H, Kawai Y, Itoh T (1998) Structural analysis of new antihypertensive peptides derived from cheese whey protein by proteinase K digestion. J Dairy Sci 81: 3131–3138.
10. Murakami M, Tonouchi H, Takahashi R, Kitazawa H, Kawai Y, et al. (2004) Structural analysis of a new anti-hypertensive peptides (β-lactasin B) isolated from a commercial whey product. J Dairy Sci 67: 1967–1974.
11. Miyashita S, Ohshige K, Watanabe J, Kimmura M, Kadoswki T, et al. (2004) Randomized controlled trial of sour milk on blood pressure in borderline hypertensive men. Am J Hypertens 17: 701–706.
12. Seppo I, Juhani K, Poussa T, Kopela R (2003) A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. Am J Clin Nutr 77: 230–338.
13. Cui ZQ, Chen X, Chen LY, Liu LS (1999) Effect of Angiotens II on the transcription and Regulation of Sarcoplasmic Reticulum Ca2+}. Biochim Biophys Acta 1437: 347–359.
14. Ojeda D, Jimenez-Ferre E, Zamilpa A, Herrera-Arellano A, Tortoriello J, et al. (2010) Inhibition of angiotensin converting enzyme (ACE) activity by the antocyanins delphinidin- and cyaniding-3-Osambubiosides from Hibiscus sabdariffa. J Ethnopharmacol 127: 7–10.
15. Martinez-Maqueda D, Miralles B, Recio I, Hernández-Ledesma B (2012) Antihypertensive peptides from food proteins: a review. Food Funct 3: 350–61.
16. Kajimoto O, Aihara K, Hirata H, Takahashi R, Nakamura Y (2001) Hypotensive effect of the tablets containing “Lactotripeptides (VPP, IPP)”. J Nutri Food 4: 51–61.
17. Mizushima S, Ohshige K, Watanabe J, Kimmura M, Kadoswki T, et al. (2004) Hypotensive effects of the hexapeptide VPPIPP on lowering SBP in vivo. It is necessary to evaluate the ACE-inhibitor effect on the blood glucose level of hyperemics simultaneously since blood sugar was positively correlated with blood pressure (systolic and diastolic), and this correlation was independent of common associations with age, body mass index (BMI) and heart rate [38]. Table 2 showed that all tested peptides and control had no significant difference in postprandial blood glucose levels in the normoglycemic and normotensive animal model. The VPPIPP and IPPVPP are potent antihypertensive nutriceuticals.

Effect of glycometabolism assay of tested hexapeptides

The results of the hexapeptide VPPIPP showed no effect on postprandial blood glucose levels in the normoglycemic and normotensive animal model. The VPPIPP and IPPVPP are potent antihypertensive nutriceuticals.

Acknowledgments

We thank Prof. Dabing Zhang's help and his laboratory for quantitative real-time PCR technique support.

Author Contributions

Conceived and designed the experiments: BQ. Performed the experiments: ED XZ. SS FZ. Analyzed the data: BQ PJ. Contributed reagents/materials/analysis tools: YD ZS DW.
33. Nurminen ML, Sipola M, Kaarto H, Pihlanto-Leppala A, Piisola K, et al. (2000) α-Lactorphín lowers blood pressure measured by radiotelemetry in normotensive and spontaneously hypertensive rats. Life Sci 66: 1535–1543.
34. Miguel M, Contreras MM, Recio I, Aleixandre A (2009) ACE-inhibitory and antihypertensive properties of a bovine casein hydrolysate. Food Chemistry 112: 211–214.
35. Asano K, Zisman LS, Bristow MR (1993) Angiotensin II receptors in the normal and failing heart. Heart Fail Rev 3: 199–208.
36. Tong XY, Evangelista A, Cohen RA (2010) Targeting the redox regulation of SERCA in vascular physiology and disease. Current Opinion in Pharmacology, 10:133–138.
37. Fang H, Luo M, Sheng Y, Li ZX, Wu YQ, et al. (2008) The antihypertensive effect of peptides: A novel alternative to drugs? Peptides 29: 1062–1071.
38. Jarrett RJ, Keen H, McCartney M, Fuller JH, Hamilton IJ (1978) Glucose tolerance and blood pressure in two population samples: their relation to diabetes mellitus and hypertension. Int J Epidemiol 7: 15–24.
39. McGrowder D, Ragoobirsingh D, Dasgupta T (2003) The effect of captopril on blood glucose, plasma insulin and blood pressure via a nitric oxide-independent mechanism in an animal model. Diabetol Croat 32: 125–131.